Table of Content

1. Executive Summary
   1. Global CAR T-Cell Therapy Market Snapshot, 2025 and 2032
   2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
   3. Key Market Trends
   4. Future Market Projections
   5. Premium Market Insights
   6. Target Antigen Developments and Key Market Events
   7. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definition
   2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Key Trends
   3. Macro-economic Factors
      1. Global Sectoral Outlook
      2. Global GDP Growth Outlook
   4. COVID-19 Impact Analysis
   5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   1. Tool Adoption Analysis
   2. Regulatory Landscape
   3. Value Chain Analysis
   4. PESTLE Analysis
   5. Porter’s Five Force Analysis
4. Price Analysis, 2024A
   1. Key Highlights
   2. Key Factors Impacting Deployment Costs
   3. Pricing Analysis, By Disease Indication
5. Global CAR T-Cell Therapy Market Outlook
   1. Key Highlights
      1. Market Volume (Units) Projections
      2. Market Size (US$ Bn) and Y-o-Y Growth
      3. Absolute $ Opportunity
   2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
      1. Historical Market Size (US$ Bn) Analysis, 2019-2024
      2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
   3. Global CAR T-Cell Therapy Market Outlook: Drug Type
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Drug Type, 2019 - 2024
      3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
         1. Yescarta
         2. Kymriah
         3. Breyanzi
         4. Abecma
         5. Carvykti
         6. Tecartus
         7. Others
      4. Market Attractiveness Analysis: Drug Type
   4. Global CAR T-Cell Therapy Market Outlook: Target Antigen
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Target Antigen, 2019 - 2024
      3. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
         1. CD19
         2. BCMA
         3. CD22
         4. CD33
         5. HER2
         6. HER1
         7. Others
      4. Market Attractiveness Analysis: Target Antigen
   5. Global CAR T-Cell Therapy Market Outlook: Disease Indication
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019 - 2024
      3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
         1. Lymphoma
         2. Leukemia
         3. Multiple Myeloma
         4. Acute Myeloid Leukemia (AML)
         5. Others
      4. Market Attractiveness Analysis: Disease Indication
6. Global CAR T-Cell Therapy Market Outlook: Region
   1. Key Highlights
   2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2024
   3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025 - 2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
   4. Market Attractiveness Analysis: Region
7. North America CAR T-Cell Therapy Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Type
      3. By Target Antigen
      4. By Disease Indication
   3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. U.S.
      2. Canada
   4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
      1. Yescarta
      2. Kymriah
      3. Breyanzi
      4. Abecma
      5. Carvykti
      6. Tecartus
      7. Others
   5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
      1. CD19
      2. BCMA
      3. CD22
      4. CD33
      5. HER2
      6. HER1
      7. Others
   6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
      1. Lymphoma
      2. Leukemia
      3. Multiple Myeloma
      4. Acute Myeloid Leukemia (AML)
      5. Others
   7. Market Attractiveness Analysis
8. Europe CAR T-Cell Therapy Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Type
      3. By Target Antigen
      4. Disease Indication
   3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Türkiye
      8. Rest of Europe
   4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
      1. Yescarta
      2. Kymriah
      3. Breyanzi
      4. Abecma
      5. Carvykti
      6. Tecartus
      7. Others
   5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
      1. CD19
      2. BCMA
      3. CD22
      4. CD33
      5. HER2
      6. HER1
      7. Others
   6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
      1. Lymphoma
      2. Leukemia
      3. Multiple Myeloma
      4. Acute Myeloid Leukemia (AML)
      5. Others
   7. Market Attractiveness Analysis
9. East Asia CAR T-Cell Therapy Market Outlook
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Drug Type
      3. By Target Antigen
      4. By Disease Indication
   3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. China
      2. Japan
      3. South Korea
   4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
      1. Yescarta
      2. Kymriah
      3. Breyanzi
      4. Abecma
      5. Carvykti
      6. Tecartus
      7. Others
   5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
      1. CD19
      2. BCMA
      3. CD22
      4. CD33
      5. HER2
      6. HER1
      7. Others
   6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
      1. Lymphoma
      2. Leukemia
      3. Multiple Myeloma
      4. Acute Myeloid Leukemia (AML)
      5. Others
   7. Market Attractiveness Analysis
10. South Asia & Oceania CAR T-Cell Therapy Market Outlook
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug Type
       3. By Target Antigen
       4. By Disease Indication
    3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. India
       2. Southeast Asia
       3. ANZ
       4. Rest of South Asia & Oceania
    4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
       1. Yescarta
       2. Kymriah
       3. Breyanzi
       4. Abecma
       5. Carvykti
       6. Tecartus
       7. Others
    5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
       1. CD19
       2. BCMA
       3. CD22
       4. CD33
       5. HER2
       6. HER1
       7. Others
    6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
       1. Lymphoma
       2. Leukemia
       3. Multiple Myeloma
       4. Acute Myeloid Leukemia (AML)
       5. Others
    7. Market Attractiveness Analysis
11. Latin America CAR T-Cell Therapy Market Outlook
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug Type
       3. By Target Antigen
       4. By Disease Indication
    3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. Brazil
       2. Mexico
       3. Rest of Latin America
    4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
       1. Yescarta
       2. Kymriah
       3. Breyanzi
       4. Abecma
       5. Carvykti
       6. Tecartus
       7. Others
    5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
       1. CD19
       2. BCMA
       3. CD22
       4. CD33
       5. HER2
       6. HER1
       7. Others
    6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
       1. Lymphoma
       2. Leukemia
       3. Multiple Myeloma
       4. Acute Myeloid Leukemia (AML)
       5. Others
    7. Market Attractiveness Analysis
12. Middle East & Africa CAR T-Cell Therapy Market Outlook
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Drug Type
       3. By Target Antigen
       4. By Disease Indication
    3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. GCC Countries
       2. Egypt
       3. South Africa
       4. Northern Africa
       5. Rest of Middle East & Africa
    4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2025 - 2032
       1. Yescarta
       2. Kymriah
       3. Breyanzi
       4. Abecma
       5. Carvykti
       6. Tecartus
       7. Others
    5. Current Market Size (US$ Bn) Analysis and Forecast, By Target Antigen, 2025 - 2032
       1. CD19
       2. BCMA
       3. CD22
       4. CD33
       5. HER2
       6. HER1
       7. Others
    6. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
       1. Lymphoma
       2. Leukemia
       3. Multiple Myeloma
       4. Acute Myeloid Leukemia (AML)
       5. Others
    7. Market Attractiveness Analysis
13. Competition Landscape
    1. Market Share Analysis, 2024
    2. Market Structure
       1. Competition Intensity Mapping By Market
       2. Competition Dashboard
    3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       1. Gilead Sciences, Inc.
          1. Overview
          2. Segments and Deployments
          3. Key Financials
          4. Market Developments
          5. Market Strategy
       2. Novartis AG
       3. Bristol-Myers Squibb Company
       4. Legend Biotech Corporation
       5. Cellectis S.A.
       6. Autolus Therapeutics Plc
       7. Adaptimmune Therapeutics plc
       8. Mustang Bio, Inc.
       9. Bellicum Pharmaceuticals, Inc.
       10. MaxCyte, Inc.
       11. Tessa Therapeutics
       12. Caribou Biosciences, Inc.
       13. Takeda Pharmaceutical Company Limited
       14. Sorrento Therapeutics, Inc.
       15. Poseida Therapeutics, Inc.
14. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations